Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travoprost 0.004% Eye · 1 trial · 2 indications
For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis
For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis
For an individual patient, two consecutive IOP measurements for each eye were taken. The mean IOP values for each individual patient's eye were rounded up to the next whole number if the value was ≥ 0.5 mmHg All IOP measurements were performed with a Goldmann applanation tonometer. All IOP measurements for any individual subject were to be performed preferably by the same operator using the same tonometer. Mean IOP for the patient's worse eye at baseline was used in the primary endpoint analysis. If both eyes were equal, then the right eye was selected for analysis
| Arm | Type | Description |
|---|---|---|
| TRAVATAN APS | EXPERIMENTAL | One drop once daily in the evening for 3 months |
| TRAVATAN | ACTIVE_COMPARATOR | One drop once daily in the evening for 3 months |
| Name | Type | Description |
|---|---|---|
| Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution | DRUG | One drop once daily in the evening for 3 months |
| Travoprost 0.004% (BAK-preserved) Eye Drops, Solution | DRUG | One drop once daily in the evening for 3 months |
Inclusion Criteria: * 18 years of age or older, either gender and any race. * Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT). * Not currently on any IOP-lowering medication or currently on a stable treatment (i.e, at least 30 days) with and IOP-lowering monotherapy. * All patients: Mean IOP...
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
Travoprost 0.004% Eye is used to treat open angle glaucoma, a condition in which elevated pressure inside the eye can damage the optic nerve. It is also studied in ocular hypertension, where eye pressure is higher than normal. The drug is a small molecule therapy delivered as an eye drop solution.
Travoprost 0.004% Eye works as an agonist of PTGFR, the prostaglandin F receptor. By activating this receptor, the drug increases the outflow of aqueous humor from the eye, which helps lower intraocular pressure. This mechanism targets the underlying cause of pressure buildup in open angle glaucoma.
Travoprost 0.004% Eye is developed by Alcon Inc., which trades under the ticker ALC. Alcon is an eye care company focused on surgical and vision care products. The travoprost 0.004% formulation is part of its ophthalmology portfolio.
Travoprost 0.004% Eye is in Phase 3 clinical development. It is an investigational therapy and has not been approved by the FDA for the studied indication. The Phase 3 program includes one completed trial evaluating its efficacy in open angle glaucoma and ocular hypertension.
Travoprost 0.004% Eye has been studied in a Phase 3 trial, NCT00848536, titled Efficacy Study of Travoprost APS Versus TRAVATAN. This completed trial enrolled 371 participants with open angle glaucoma or ocular hypertension. It was randomized, double blind, and active controlled, with participants aged 18 years and older.
Yes, Travoprost 0.004% Eye is also known as Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution. The POLYQUAD preservation system distinguishes this formulation. Both names refer to the same travoprost 0.004% ophthalmic solution developed by Alcon for open angle glaucoma.